- Home
- SRRK vs EXLS Comparison
SRRK vs EXLS Comparison
Compare SRRK & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRRK | EXLS |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.8B |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | SRRK | EXLS |
|---|---|---|
| Price | $46.81 | $31.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $56.17 | $46.80 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.61 |
| Revenue Next Year | $534.24 | $10.55 |
| P/E Ratio | ★ N/A | $73.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $26.94 |
| 52 Week High | $51.63 | $48.54 |
Technical Indicators
Market Signals| Indicator | SRRK | EXLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 56.23 |
| Support Level | $45.59 | $29.11 |
| Resistance Level | $47.96 | $32.32 |
| Average True Range (ATR) | 1.67 | 1.07 |
| MACD | -0.35 | 0.12 |
| Stochastic Oscillator | 25.92 | 60.63 |
Price Performance
Historical ComparisonAbout SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.